Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
PT-141 is FDA-approved (Vyleesi 2019) for hypoactive sexual desire disorder in women
Insights from a clinical audit
Money-saving packages keep repeat visits easy
In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
If it sat out at room temp for more than 4 hours, toss it
Key Takeaway: Liposomal delivery uses a protective fatty shell to bypass stomach acid, increasing absorption at the cellular level while reducing the risk of digestive irritation
US$ 20.38
US$ 28.31
US$ 29.15
US$ 26.47
US$ 28.86
US$ 29.59
